GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nemaura Medical Inc (OTCPK:NMRD) » Definitions » ROC %

Nemaura Medical (Nemaura Medical) ROC % : -27.76% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Nemaura Medical ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Nemaura Medical's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was -27.76%.

As of today (2024-04-27), Nemaura Medical's WACC % is 26.83%. Nemaura Medical's ROC % is -56.93% (calculated using TTM income statement data). Nemaura Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Nemaura Medical ROC % Historical Data

The historical data trend for Nemaura Medical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nemaura Medical ROC % Chart

Nemaura Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,248.81 -875.61 -110.04 -50.61 -39.32

Nemaura Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.05 -132.51 -37.46 -37.46 -27.76

Nemaura Medical ROC % Calculation

Nemaura Medical's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2023 is calculated as:

ROC % (A: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2022 ) + Invested Capital (A: Mar. 2023 ))/ count )
=-8.615 * ( 1 - 0% )/( (21.902 + 21.916)/ 2 )
=-8.615/21.909
=-39.32 %

where

Nemaura Medical's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-6.164 * ( 1 - 0% )/( (21.77 + 22.64)/ 2 )
=-6.164/22.205
=-27.76 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nemaura Medical  (OTCPK:NMRD) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Nemaura Medical's WACC % is 26.83%. Nemaura Medical's ROC % is -56.93% (calculated using TTM income statement data). Nemaura Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Nemaura Medical ROC % Related Terms

Thank you for viewing the detailed overview of Nemaura Medical's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nemaura Medical (Nemaura Medical) Business Description

Traded in Other Exchanges
N/A
Address
57 West 57th Street, New York, NY, USA, 10019
Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.
Executives
Bashir Timol director, 10 percent owner, officer: Chief Business Officer C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Chowdhury Dewan Fazlul Hoque director, 10 percent owner, officer: CEO & President CHAMWOOD BUILDING, HOLYWELL PARK, ASHBURY ROAD, LOUGHBOROUGH LEICS X0 LE113AQ
Salim Natha director LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Justin James Mclarney officer: Chief Financial Officer C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Sufyan Ismail 10 percent owner C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Thomas Peter Moore director C/O NEMAURA MEDICAL, INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Timothy Christopher Johnson director C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Iain Anderson officer: CFO LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Kathryn Farrar officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Julie Pomeroy officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Richard Toon officer: Technical & Bus. Dev. Manager C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT